Literature DB >> 12821453

Influences of methodological variables on susceptibility testing of caspofungin against Candida species and Aspergillus fumigatus.

C Bartizal1, F C Odds.   

Abstract

The influences of test variables on the outcome of susceptibility testing with caspofungin were tested with isolates of Candida spp. and Aspergillus fumigatus. Among six growth conditions tested with a range of inoculum sizes, the highest control growth yields were obtained in Sabouraud broth for all fungi, followed by RPMI 1640 (pH 7) for Candida spp. and antibiotic medium 3 (AM3) for A. fumigatus. RPMI 1640 gave unacceptably low growth yields with A. fumigatus. The caspofungin MICs under these various conditions ranged over more than 4 twofold dilutions for 7 of 16 fungi tested when a 50% inhibition (50% inhibitory concentration [IC(50)]) endpoint was used and for 12 of 16 fungi tested when an 80% inhibition (IC(80)) endpoint was used. A multifactorial design to study the influences of six test variables on control growth and the MIC showed that, for 14 isolates of Candida spp., the glucose concentration and the medium composition were the most common factors significantly influencing both control growth yields and the MIC. For eight A. fumigatus isolates, incubation time (24 versus 48 h) and temperature (30 versus 35 degrees C) significantly affected control optical density (OD) values, while growth medium (AM3 versus Sabouraud broth) was the most common process variable affecting the MICs. Tests with AM3 from three suppliers showed significant variations in control OD values related to supplier, but IC(50)s fell within a 2- or 3-dilution range for 19 (86%) of the 22 isolates tested. We recommend that, at present, AM3 is superior to RPMI 1640 for testing of the susceptibilities of both yeasts and filamentous fungi to caspofungin and that a minimum incubation time of 48 h is necessary to test A. fumigatus adequately.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12821453      PMCID: PMC161835          DOI: 10.1128/AAC.47.7.2100-2107.2003

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  19 in total

1.  In vitro activity of the new echinocandin antifungal, MK-0991, against common and uncommon clinical isolates of Candida species.

Authors:  F Barchiesi; A M Schimizzi; A W Fothergill; G Scalise; M G Rinaldi
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1999-04       Impact factor: 3.267

2.  Disk diffusion method for determining susceptibilities of Candida spp. to MK-0991.

Authors:  M Lozano-Chiu; P W Nelson; V L Paetznick; J H Rex
Journal:  J Clin Microbiol       Date:  1999-05       Impact factor: 5.948

Review 3.  Antifungal susceptibility testing: practical aspects and current challenges.

Authors:  J H Rex; M A Pfaller; T J Walsh; V Chaturvedi; A Espinel-Ingroff; M A Ghannoum; L L Gosey; F C Odds; M G Rinaldi; D J Sheehan; D W Warnock
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

4.  In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi.

Authors:  M A Pfaller; F Marco; S A Messer; R N Jones
Journal:  Diagn Microbiol Infect Dis       Date:  1998-04       Impact factor: 2.803

5.  Caspofungin.

Authors:  G M Keating; B Jarvis
Journal:  Drugs       Date:  2001       Impact factor: 9.546

6.  Comparison of In vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts.

Authors:  A Espinel-Ingroff
Journal:  J Clin Microbiol       Date:  1998-10       Impact factor: 5.948

7.  Quality control limits for broth microdilution susceptibility tests of ten antifungal agents.

Authors:  A L Barry; M A Pfaller; S D Brown; A Espinel-Ingroff; M A Ghannoum; C Knapp; R P Rennie; J H Rex; M G Rinaldi
Journal:  J Clin Microbiol       Date:  2000-09       Impact factor: 5.948

8.  Susceptibility testing of pathogenic fungi with itraconazole: a process analysis of test variables.

Authors:  B Rambali; J A Fernandez; L Van Nuffel; F Woestenborghs; L Baert; D L Massart; F C Odds
Journal:  J Antimicrob Chemother       Date:  2001-08       Impact factor: 5.790

9.  International surveillance of blood stream infections due to Candida species in the European SENTRY Program: species distribution and antifungal susceptibility including the investigational triazole and echinocandin agents. SENTRY Participant Group (Europe).

Authors:  M A Pfaller; R N Jones; G V Doern; A C Fluit; J Verhoef; H S Sader; S A Messer; A Houston; S Coffman; R J Hollis
Journal:  Diagn Microbiol Infect Dis       Date:  1999-09       Impact factor: 2.803

10.  In vitro susceptibility testing methods for caspofungin against Aspergillus and Fusarium isolates.

Authors:  S Arikan; M Lozano-Chiu; V Paetznick; J H Rex
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

View more
  28 in total

1.  Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species.

Authors:  Frank C Odds; Mary Motyl; Roberto Andrade; Jacques Bille; Emilia Cantón; Manuel Cuenca-Estrella; Amanda Davidson; Christian Durussel; David Ellis; Elyse Foraker; Annette W Fothergill; Mahmoud A Ghannoum; Robert A Giacobbe; Miguel Gobernado; Rosemary Handke; Michel Laverdière; Wendy Lee-Yang; William G Merz; Luis Ostrosky-Zeichner; Javier Pemán; Sophia Perea; John R Perfect; Michael A Pfaller; Laurie Proia; John H Rex; Michael G Rinaldi; Juan-Luis Rodriguez-Tudela; Wiley A Schell; Christine Shields; Deanna A Sutton; Paul E Verweij; David W Warnock
Journal:  J Clin Microbiol       Date:  2004-08       Impact factor: 5.948

2.  Recent exposure to caspofungin or fluconazole influences the epidemiology of candidemia: a prospective multicenter study involving 2,441 patients.

Authors:  Olivier Lortholary; Marie Desnos-Ollivier; Karine Sitbon; Arnaud Fontanet; Stéphane Bretagne; Françoise Dromer
Journal:  Antimicrob Agents Chemother       Date:  2010-11-15       Impact factor: 5.191

3.  Sensititre YeastOne caspofungin susceptibility testing of Candida clinical isolates: correlation with results of NCCLS M27-A2 multicenter study.

Authors:  Emilia Cantón; Javier Pemán; Miguel Gobernado; Elena Alvarez; Fernando Baquero; Ramón Cisterna; Joaquina Gil; Estrella Martín-Mazuelos; Carmen Rubio; Aurora Sánchez-Sousa; Carmen Serrano
Journal:  Antimicrob Agents Chemother       Date:  2005-04       Impact factor: 5.191

4.  Candida albicans and Candida dubliniensis respond differently to echinocandin antifungal agents in vitro.

Authors:  Mette D Jacobsen; Julie A Whyte; Frank C Odds
Journal:  Antimicrob Agents Chemother       Date:  2007-02-16       Impact factor: 5.191

Review 5.  Epidemiology of invasive candidiasis: a persistent public health problem.

Authors:  M A Pfaller; D J Diekema
Journal:  Clin Microbiol Rev       Date:  2007-01       Impact factor: 26.132

6.  Comparative in vitro activities of caspofungin and micafungin, determined using the method of the European Committee on Antimicrobial Susceptibility Testing, against yeast isolates obtained in France in 2005-2006.

Authors:  E Dannaoui; O Lortholary; D Raoux; M E Bougnoux; G Galeazzi; C Lawrence; D Moissenet; I Poilane; D Hoinard; F Dromer
Journal:  Antimicrob Agents Chemother       Date:  2007-12-10       Impact factor: 5.191

7.  In vitro study of Candida tropicalis isolates exhibiting paradoxical growth in the presence of high concentrations of caspofungin.

Authors:  G Sóczó; G Kardos; I Varga; B Kelentey; R Gesztelyi; L Majoros
Journal:  Antimicrob Agents Chemother       Date:  2007-10-08       Impact factor: 5.191

8.  Susceptibility profiles of amphotericin B and posaconazole against clinically relevant mucorales species under hypoxic conditions.

Authors:  Elisabeth Maurer; Ulrike Binder; Manuela Sparber; Michaela Lackner; Rita Caramalho; Cornelia Lass-Flörl
Journal:  Antimicrob Agents Chemother       Date:  2014-12-01       Impact factor: 5.191

9.  Paradoxical effect of caspofungin: reduced activity against Candida albicans at high drug concentrations.

Authors:  David A Stevens; Marife Espiritu; Rachana Parmar
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

10.  Further standardization of broth microdilution methodology for in vitro susceptibility testing of caspofungin against Candida species by use of an international collection of more than 3,000 clinical isolates.

Authors:  M A Pfaller; S A Messer; L Boyken; C Rice; S Tendolkar; R J Hollis; D J Diekema
Journal:  J Clin Microbiol       Date:  2004-07       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.